keyword
https://read.qxmd.com/read/38651826/mutant-ras-driven-secretome-causes-skeletal-muscle-defects-in-breast-cancer
#1
JOURNAL ARTICLE
Ruizhong Wang, Aditi S Khatpe, Brijesh Kumar, Henry Elmer Mang, Katie Batic, Adedeji K Adebayo, Harikrishna Nakshatri
Cancer-induced skeletal muscle defects differ in severity between individuals with the same cancer type. Cancer subtype-specific genomic aberrations are suggested to mediate these differences, but experimental validation studies are very limited. We utilized three different breast cancer patient-derived xenograft (PDX) models to correlate cancer subtype with skeletal muscle defects. PDXs were derived from brain metastasis of triple negative breast cancer (TNBC), Estrogen Receptor-positive/Progesterone Receptor-positive (ER+/PR+) primary breast cancer from a BRCA2-mutation carrier, and pleural effusion from an ER+/PR- breast cancer...
April 23, 2024: Cancer Res Commun
https://read.qxmd.com/read/38640890/meet-the-authors-guy-zoltsman-and-rina-rosenzweig
#2
JOURNAL ARTICLE
Guy Zoltsman, Rina Rosenzweig
We talk to first and last authors Guy Zoltsman and Rina Rosenzweig about their paper, "A unique chaperoning mechanism in Class A JDPs recognizes and stabilizes mutant p53," how every result may be important in the right context, and the importance to Rina that her lab is an encouraging and collaborative place.
April 18, 2024: Molecular Cell
https://read.qxmd.com/read/38633919/prognostic-value-of-atrx-and-p53-status-in-high-grade-glioma-patients-in-morocco
#3
JOURNAL ARTICLE
Asmae Squalli Houssaini, Salma Lamrabet, Nadia Senhaji, Mohammed Sekal, Jean Paul Nshizirungu, Hajar Mahfoudi, Samira Elfakir, Mehdi Karkouri, Sanae Bennis
INTRODUCTION: Glioblastoma and astrocytoma, grade 4, are the most common and aggressive brain tumors. Several biomarkers, such as the isocitrate dehydrogenase mutation (IDH-1), alpha-thalassemia/mental retardation, and the X-linked mutation (ATRX), enable more accurate glioma classification and facilitate patient management. This study aimed to determine the prognostic value of clinical and molecular factors (IDH, TP53, and ATRX mutations). We also studied the relationship between these molecular markers and the overall survival (OS) of 126 patients with grade 4 glioblastoma/astrocytoma...
March 2024: Curēus
https://read.qxmd.com/read/38617260/distinct-genomic-and-immunologic-tumor-evolution-in-germline-tp53-driven-breast-cancers
#4
Nabamita Boruah, David Hoyos, Renyta Moses, Ryan Hausler, Heena Desai, Anh N Le, Madeline Good, Gregory Kelly, Ashvathi Raghavakaimal, Maliha Tayeb, Mohana Narasimhamurthy, Abigail Doucette, Peter Gabriel, Michael J Feldman, Jinae Park, Miguel Lopez de Rodas, Kurt A Schalper, Shari B Goldfarb, Anupma Nayak, Arnold J Levine, Benjamin D Greenbaum, Kara N Maxwell
Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of TP53 with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes BAX and TP53I3 failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue...
April 5, 2024: bioRxiv
https://read.qxmd.com/read/38584451/genomic-and-pathologic-profiling-of-very-well-differentiated-gastric-adenocarcinoma-of-intestinal-type-a-study-with-emphasis-on-diffuse-type-transformation
#5
JOURNAL ARTICLE
Hirofumi Rokutan, Yasuhito Arai, Akiko Kunita, Satoshi Yamasaki, Hiromi Nakamura, Natsuko Hama, Atsuhito Nakayama, Fumie Hosoda, Yasushi Totoki, Mitsuhiro Fujishiro, Yasuyuki Seto, Tatsuhiro Shibata, Tetsuo Ushiku
Very well-differentiated adenocarcinoma of intestinal type is a distinct subtype of gastric cancer characterized by anastomosing glands with a hand-in-hand pattern and low-grade cytologic atypia resembling intestinal metaplasia. This is a slow-growing neoplasm with an indolent clinical course; however, a subset demonstrates transformation into adenocarcinoma with higher-grade histology, typically diffuse-type carcinoma, and behaves aggressively. This study aimed to better characterize the genomic and pathologic features, with a focus on factors associated with diffuse-type transformation...
April 8, 2024: American Journal of Surgical Pathology
https://read.qxmd.com/read/38581732/discovery-of-ganoderic-acid-a-gaa-protacs-as-mdm2-protein-degraders-for-the-treatment-of-breast-cancer
#6
JOURNAL ARTICLE
Yan Li, Guangyu Li, Chenwei Zuo, Xiaolin Wang, Fang Han, Yi Jia, Hai Shang, Yu Tian
Breast cancer is one of the most common female malignant tumors, with triple-negative breast cancer (TNBC) being the most specific, highly invasive, metastatic and associated with a poor prognosis. Our previous study showed that the natural product ganoderic acid A (GAA) has a certain affinity for MDM2. In this study, two series of novel GAA PROTACs C1-C10 and V1-V10 were designed and synthesized for the treatment of breast cancer. The antitumor activity of these compounds was evaluated against four human tumor cell lines (MCF-7, MDA-MB-231, SJSA-1, and HepG2)...
April 5, 2024: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/38580884/genome-wide-crispr-screens-identify-novel-regulators-of-wild-type-and-mutant-p53-stability
#7
JOURNAL ARTICLE
YiQing Lü, Tiffany Cho, Saptaparna Mukherjee, Carmen Florencia Suarez, Nicolas S Gonzalez-Foutel, Ahmad Malik, Sebastien Martinez, Dzana Dervovic, Robin Hyunseo Oh, Ellen Langille, Khalid N Al-Zahrani, Lisa Hoeg, Zhen Yuan Lin, Ricky Tsai, Geraldine Mbamalu, Varda Rotter, Patricia Ashton-Prolla, Jason Moffat, Lucia Beatriz Chemes, Anne-Claude Gingras, Moshe Oren, Daniel Durocher, Daniel Schramek
Tumor suppressor p53 (TP53) is frequently mutated in cancer, often resulting not only in loss of its tumor-suppressive function but also acquisition of dominant-negative and even oncogenic gain-of-function traits. While wild-type p53 levels are tightly regulated, mutants are typically stabilized in tumors, which is crucial for their oncogenic properties. Here, we systematically profiled the factors that regulate protein stability of wild-type and mutant p53 using marker-based genome-wide CRISPR screens. Most regulators of wild-type p53 also regulate p53 mutants, except for p53 R337H regulators, which are largely private to this mutant...
April 5, 2024: Molecular Systems Biology
https://read.qxmd.com/read/38562170/prognostic-significance-of-pyroptosis-associated-molecules-in-endometrial-cancer-a-comprehensive-immunohistochemical-analysis
#8
JOURNAL ARTICLE
Seong-Chan Ha, Yeon Soo Park, Jisup Kim
INTRODUCTION: Endometrial cancer, the most prevalent malignancy of the female genital tract, has a concerningly poor prognosis when diagnosed in advanced stages, with limited targeted therapy options available for advanced or recurrent cases. Pyroptosis, a type of nonapoptotic cell death mediated by caspase-1, has shown potential antitumor effects in various tumors. NLRP3, a cytosolic sensor, initiates the canonical pyroptotic pathway, leading to caspase-1 activation, subsequent gasdermin D cleavage, and plasma membrane pore formation...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38560504/dna-delivered-monoclonal-antibodies-targeting-the-p53-r175h-mutant-epitope-inhibit-tumor-development-in-mice
#9
JOURNAL ARTICLE
Dafei Chai, Xu Wang, Praveen Neeli, Shan Zhou, Xingfang Yu, Kanaga Sabapathy, Yong Li
The tumor suppressor p53 is the most common mutated gene in cancer, with the R175H as the most frequent p53 missense mutant. However, there are currently no approved targeted therapies or immunotherapies against mutant p53. Here, we characterized and investigated a monoclonal antibody (mAb) that recognizes the mutant p53-R175H for its affinity, specificity, and activity against tumor cells in vitro . We then delivered DNA plasmids expressing the anti-R175H mAb or a bispecific antibody (BsAb) into mice to evaluate their therapeutic effects...
July 2024: Genes & Diseases
https://read.qxmd.com/read/38559270/epigenetic-reprogramming-of-autophagy-drives-mutant-idh1-glioma-progression-and-response-to-radiation
#10
Felipe J Núñez, Kaushik Banerjee, Anzar A Mujeeb, Ava Mauser, Claire E Tronrud, Ziwen Zhu, Ayman Taher, Padma Kadiyala, Stephen V Carney, Maria B Garcia-Fabiani, Andrea Comba, Mahmoud S Alghamri, Brandon L McClellan, Syed M Faisal, Zeribe C Nwosu, Hanna S Hong, Tingting Qin, Maureen A Sartor, Mats Ljungman, Shi-Yuan Cheng, Henry D Appelman, Pedro R Lowenstein, Joerg Lahann, Costas A Lyssiotis, Maria G Castro
UNLABELLED: Mutant isocitrate dehydrogenase 1 (mIDH1; IDH1 R132H ) exhibits a gain of function mutation enabling 2-hydroxyglutarate (2HG) production. 2HG inhibits DNA and histone demethylases, inducing epigenetic reprogramming and corresponding changes to the transcriptome. We previously demonstrated 2HG-mediated epigenetic reprogramming enhances DNA-damage response and confers radioresistance in mIDH1 gliomas harboring p53 and ATRX loss of function mutations. In this study, RNA-seq and ChIP-seq data revealed human and mouse mIDH1 glioma neurospheres have downregulated gene ontologies related to mitochondrial metabolism and upregulated autophagy...
March 13, 2024: bioRxiv
https://read.qxmd.com/read/38553451/nanoparticles-targeting-mutant-p53-overcome-chemoresistance-and-tumor-recurrence-in-non-small-cell-lung-cancer
#11
JOURNAL ARTICLE
Yu-Yang Bi, Qiu Chen, Ming-Yuan Yang, Lei Xing, Hu-Lin Jiang
Non-small cell lung cancer (NSCLC) shows high drug resistance and leads to low survival due to the high level of mutated Tumor Protein p53 (TP53). Cisplatin is a first-line treatment option for NSCLC, and the p53 mutation is a major factor in chemoresistance. We demonstrate that cisplatin chemotherapy increases the risk of TP53 mutations, further contributing to cisplatin resistance. Encouragingly, we find that the combination of cisplatin and fluvastatin can alleviate this problem. Therefore, we synthesize Fluplatin, a prodrug consisting of cisplatin and fluvastatin...
March 29, 2024: Nature Communications
https://read.qxmd.com/read/38552605/p53-a-tale-of-complexity-and-context
#12
JOURNAL ARTICLE
Moshe Oren, Carol Prives
The story of p53 is illuminating. Despite widespread attention, the tumor-suppressive functions of wild-type p53 or the oncogenic activities of its cancer-associated mutants are still not fully understood, and our discoveries have not yet led to major therapeutic breakthroughs. There is still much to learn about this fascinating protein.
March 28, 2024: Cell
https://read.qxmd.com/read/38547608/loss-of-mutant-p53-in-hacat-keratinocytes-promotes-cadmium-induced-keratin-17-expression-and-cell-death
#13
JOURNAL ARTICLE
Daniil Romashin, Alexander Rusanov, Tatiana Tolstova, Alexandra Varshaver, Alexander Netrusov, Peter Kozhin, Nataliya Luzgina
BACKGROUND: Cadmium exposure induces dermatotoxicity and epidermal barrier disruption and leads to the development of various pathologies. HaCaT cells are immortalized human keratinocytes that are widely used as alternatives to primary human keratinocytes, particularly for evaluating cadmium toxicity. HaCaT cells bear two gain-of-function (GOF) mutations in the TP53 gene, which strongly affect p53 function. Mutant forms of p53 are known to correlate with increased resistance to various stimuli, including exposure to cytotoxic substances...
March 26, 2024: Biochemical and Biophysical Research Communications
https://read.qxmd.com/read/38547292/control-of-cell-proliferation-by-memories-of-mitosis
#14
JOURNAL ARTICLE
Franz Meitinger, Hazrat Belal, Robert L Davis, Mallory B Martinez, Andrew K Shiau, Karen Oegema, Arshad Desai
Mitotic duration is tightly constrained, and extended mitosis is characteristic of problematic cells prone to chromosome missegregation and genomic instability. We show here that mitotic extension leads to the formation of p53-binding protein 1 (53BP1)-ubiquitin-specific protease 28 (USP28)-p53 protein complexes that are transmitted to, and stably retained by, daughter cells. Complexes assembled through a Polo-like kinase 1-dependent mechanism during extended mitosis and elicited a p53 response in G1 that prevented the proliferation of the progeny of cells that experienced an approximately threefold extended mitosis or successive less extended mitoses...
March 29, 2024: Science
https://read.qxmd.com/read/38547169/p53-dosage-can-impede-krasg12d-and-krasq61r-mediated-tumorigenesis
#15
JOURNAL ARTICLE
Özgün Le Roux, Jeffery I Everitt, Christopher M Counter
Mice engineered with a G12D versus Q61R mutation in Kras exhibited differences in tumorigenesis. Namely, the incidence or grade of oral or forestomach squamous epithelial lesions was more prevalent in the KrasG12D background while hematolymphopoietic disease was more prevalent in the KrasQ61R background. Loss of the Trp53 gene encoding the tumor suppressor p53 enhances the ability of oncogenic Kras to initiate tumorigenesis in carcinogen and genetic models of lung cancer. Conversley, an extra copy of Trp53 (Super p53) was recently shown to suppress Kras-induced tumorigenesis in a genetic model of this disease...
2024: PloS One
https://read.qxmd.com/read/38539819/-calocedrus-formosana-essential-oils-induce-ros-mediated-autophagy-and-apoptosis-by-targeting-sirt1-in-colon-cancer-cells
#16
JOURNAL ARTICLE
Atikul Islam, Yu-Chun Chang, Nai-Wen Tsao, Sheng-Yang Wang, Pin Ju Chueh
Colorectal cancer is the most common cancer that affects both sexes and has a poor prognosis due to aggressiveness and chemoresistance. Essential oils isolated from Calocedrus formosana (CF-EOs) have been shown to demonstrate anti-termite, antifungal, anti-mosquito, and anti-microbial activities. However, the anticancer effects of CF-EOs are not yet fully understood. Therefore, the present study aimed to explore the molecular mechanism underlying CF-EOs-mediated anti-proliferative activity in colon cancer cells...
February 26, 2024: Antioxidants (Basel, Switzerland)
https://read.qxmd.com/read/38539507/emerging-advances-in-endometrial-cancer-integration-of-molecular-classification-into-staging-for-enhanced-prognostic-accuracy-and-implications-for-racial-disparities
#17
REVIEW
Joy Ogunmuyiwa, Vonetta Williams
Since the 2009 FIGO staging update, focused exclusively on the anatomic extent of disease, there have been several advances in the understanding of the pathologic and molecular features of endometrial cancer. In a significant departure from the 2009 FIGO staging system, the 2023 FIGO staging update integrates both histopathological and molecular classification. With the inclusion of non-anatomic pathologic parameters such as histology, tumor grade, lymphovascular space invasion, and molecular subtype, the 2023 FIGO staging update aims to create more clinically relevant substages that improve prognostic value and allows for more individualized treatment paradigms...
March 16, 2024: Cancers
https://read.qxmd.com/read/38539458/actin-dependent-mechanism-of-tumor-progression-induced-by-a-dysfunction-of-p53-tumor-suppressor
#18
JOURNAL ARTICLE
Natalia Khromova, Maria Vasileva, Vera Dugina, Dmitry Kudlay, Peter Chumakov, Sergei Boichuk, Pavel Kopnin
Cancer cell aggressiveness, marked by actin cytoskeleton reconfiguration critical for metastasis, may result from an imbalanced ratio favoring γ-actin. Dysfunctional p53 emerges as a key regulator of invasiveness and migration in various cancer cells, both in vitro and in vivo. P53 inactivation (via mutants R175H, R248W, R273H, or TP53 repression) significantly enhanced the migration, invasion, and proliferation of human lung adenocarcinoma A549 cells in vitro and in vivo, facilitating intrapulmonary xenograft metastasis in athymic mice...
March 11, 2024: Cancers
https://read.qxmd.com/read/38523676/twenty-years-of-gendicine%C3%A2-rad-p53-cancer-gene-therapy-the-first-in-class-human-cancer-gene-therapy-in-the-era-of-personalized-oncology
#19
REVIEW
Li Qi, Guiqing Li, Peipei Li, Hongwei Wang, Xiaolong Fang, Tongchuan He, Jingjing Li
Genetic mutations in TP53 contribute to human malignancies through various means. To date, there have been a variety of therapeutic strategies targeting p53, including gene therapy to restore normal p53 function, mutant p53 rescue, inhibiting the MDM2-p53 interaction, p53-based vaccines, and a number of other approaches. This review focuses on the functions of TP53 and discusses the aberrant roles of mutant p53 in various types of cancer. Recombinant human p53 adenovirus, trademarked as Gendicine, which is the first anti-tumor gene therapy drug, has made tremendous progress in cancer gene therapy...
July 2024: Genes & Diseases
https://read.qxmd.com/read/38518213/incidence-and-risk-factors-for-recurrence-and-progression-of-hpv-independent-vulvar-intraepithelial-neoplasia
#20
JOURNAL ARTICLE
Féline O Voss, Marc van Beurden, Koen J Veelders, Annette H Bruggink, Renske D M Steenbergen, Johannes Berkhof, Maaike C G Bleeker
OBJECTIVES: Human papillomavirus (HPV)-independent vulvar intraepithelial neoplasia (VIN) is a rare yet aggressive precursor lesion of vulvar cancer. Our objectives were to estimate its long-term incidence, the risk of recurrent disease and progression to vulvar cancer, and risk factors thereof. MATERIALS AND METHODS: Patients with HPV-independent VIN between 1991 and 2019 in a selected region were identified from the Dutch Nationwide Pathology Databank (Palga)...
April 1, 2024: Journal of Lower Genital Tract Disease
keyword
keyword
74906
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.